AtlasCancersNeoplasms

Kidney cancer

3Curable in someAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020252004 — Bevacizumab approved (FDA)2005 — Sorafenib approved (FDA)2006 — Sunitinib approved (FDA)2007 — Temsirolimus approved (FDA)2009 — Pazopanib approved (FDA)2009 — Everolimus approved (FDA)2011 — Ipilimumab approved (FDA)2012 — Axitinib approved (FDA)2012 — Cabozantinib approved (FDA)2014 — Pembrolizumab approved (FDA)2015 — Nivolumab approved (FDA)2015 — Lenvatinib approved (FDA)2017 — Tivozanib approved (FDA)2021 — Belzutifan approved (FDA)
2004: Drug approval — Bevacizumab approved (FDA). 2005: Drug approval — Sorafenib approved (FDA). 2006: Drug approval — Sunitinib approved (FDA). 2007: Drug approval — Temsirolimus approved (FDA). 2009: Drug approval — Pazopanib approved (FDA). 2009: Drug approval — Everolimus approved (FDA). 2011: Drug approval — Ipilimumab approved (FDA). 2012: Drug approval — Axitinib approved (FDA). 2012: Drug approval — Cabozantinib approved (FDA). 2014: Drug approval — Pembrolizumab approved (FDA). 2015: Drug approval — Nivolumab approved (FDA). 2015: Drug approval — Lenvatinib approved (FDA). 2017: Drug approval — Tivozanib approved (FDA). 2021: Drug approval — Belzutifan approved (FDA)

What's being tested now

2000: 1 trials started2002: 1 trials started2003: 1 trials started2004: 2 trials started2005: 2 trials started2007: 1 trials started2008: 1 trials started2009: 3 trials started2010: 4 trials started2011: 2 trials started2012: 2 trials started2013: 4 trials started2014: 2 trials started2015: 7 trials started2016: 7 trials started2017: 16 trials started2018: 17 trials started2019: 21 trials started2020: 29 trials started2021: 34 trials started2022: 48 trials started2023: 73 trials started2024: 74 trials started2025: 119 trials started2026: 96 trials started2000201020202026119

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 533 active Chromophobe Renal Cell Carcinoma trials on Clin2 →

Related

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.